Actively Recruiting
Evaluation of DS-3939a Alone or With Other Anticancer Agents in Participants With Solid Tumors Including Advanced Non-Small Cell Lung Cancer
Led by Daiichi Sankyo · Updated on 2026-10-28
400
Participants Needed
76
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and effectiveness of DS-3939a, alone or combined with other cancer treatments, in people with solid tumors, including locally advanced unresectable or metastatic non-squamous non-small cell lung cancer NSCLC. The study is an open-label trial with two independent substudies focusing on different patient groups and treatment combinations, including immunotherapy and chemotherapy. It aims to better understand how these treatments work in advanced lung cancer cases. Participants receive intravenous infusions of DS-3939a every three weeks, either alone or combined with pembrolizumab, carboplatin, pemetrexed, or DS-1103a, depending on their subgroup. The study has two parts for each substudy dose escalation Part 1 to find the recommended dose, followed by dose expansion Part 2 where participants are randomized to different treatment groups. Treatments continue until disease progression or other reasons for stopping treatment. During the study, participants will have regular assessments including imaging scans to monitor tumor response based on RECIST v1.1 criteria, safety evaluations, and blood tests to measure drug levels. Researchers will track side effects, tumor shrinkage, disease control, and survival over several years. The study also includes long-term monitoring of drug concentrations and immune responses. Participants can expect frequent visits for treatments and evaluations throughout the study period.
CONDITIONS
Brief Title
A Study of DS-3939a in Participants With Solid Tumors
Research Team
D
Daiichi Sankyo Contact for Clinical Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here